Vincerx Pharma, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vincerx Pharma, Inc. Vincerx Pharma, Inc. (VINC) operates as a clinical-stage biopharmaceutical company focused on developing differentiated therapies to address unmet needs in cancer treatment through its proprietary VersAptx bioconjugation platform. The platform enables modular combinations of targeting moieties, linkers, and payloads to create antibody-drug conjugates (ADCs) such as VIP943 (anti-CD123 ADC for relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndromes, and B-cell acute lymphoblastic leukemia in Phase 1 dose-escalation), VIP924 (anti-CXCR5 ADC for B-cell malignancies in preclinical development), and small molecule-drug conjugates (SMDCs) including VIP236 (αvβ3-targeted optimized camptothecin SMDC for advanced or metastatic solid tumors in Phase 1 dose-escalation); it also incorporates CellTrapper technology to reduce payload permeability and enhance safety. Additional assets include enitociclib, a highly selective CDK9 inhibitor in an NIH-sponsored Phase 1 dose-escalation trial in combination with venetoclax and prednisone for diffuse large B-cell lymphoma and peripheral T-cell lymphoma. The company targets hematologic malignancies and solid tumors, with operations in the United States and a research facility in Germany; Vincerx Pharma, Inc. was founded in 2019 (originally as Vincera Pharma, Inc., with a name change in January 2021) and is headquartered in San Mateo, California. Recent developments include Phase 1 enrollment progress for VIP236 (20 patients dosed across schedules, with preliminary data presented at the 2024 AACR Annual Meeting showing a favorable safety profile and dose-dependent activity) and VIP943 (9 patients dosed, with pharmacokinetic data at AACR 2024 confirming low circulating payload and preliminary clinical data anticipated around the 2024 EHA Annual Meeting); preclinical advancements for VIP924 with an IND planned for late 2025 or early 2026 pending funding; and promising early efficacy signals for enitociclib combinations, including partial responses in PTCL and double-hit DLBCL at sub-efficacious doses. Terminated merger pursuits in early 2025 with Oqory, Inc. (anti-TROP2 ADC asset) and QumulusAI (AI computing) reflect strategic refocusing on the core oncology pipeline.
Contrasting Whitehawk Therapeutics (NASDAQ:WHWK) & Vincerx Pharma (NASDAQ:VINC)
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC)
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC)
Evelo Biosciences (NASDAQ:EVLO) vs. Vincerx Pharma (NASDAQ:VINC) Financial Analysis
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives
Vincerx Pharma, Inc. Announces Reverse Stock Split
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
What Makes Vincerx Pharma (VINC) a New Buy Stock
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates